Posts for Ticker ‘OSIR’

Top Day Trader Alerts (AIG, HLCS, OSIR, ITLN, SPDR)

We already saw many bounces from contact notifications on Wall Street, so many traders may still be off or getting slowly back in the saddle.  That being said, some of the active trader alerts are not as robust or as strong as they might be on other days that are not after a holiday.  Here are the Tuesday day trader alerts with more detailed trading volume and price analysis in the links over at VSInvestor.com:

American International Group, Inc. (AIG) is getting hit on another analyst downgrade.

Helicos BioSciences Corporation (NASDAQ: HLCS) is up big after selling four Helicos Genetic Analysis Systems. -JON OGG

Osiris Therapeutics, Inc. (NASDAQ: OSIR) is getting clobbered and will be active in stocks and options on an exponential basis on negative stem cell study news.

Intellon Corp. (NASDAQ: ITLN) is soaring by 45% on a buyout offer…

SPDR Gold Shares (NYSE: GLD) is very active because of $1,000 gold…

You can join our open email distribution list which goes out several times per week if you wish to be notified by email when the top day trader alerts hit, along with news of IPO’s, key offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG
SEPTEMBER 8, 2009

Posted on: September 8, 2009 – 9:26 am in After-Hours Activity, Options, Pre-Market Activity, Trading Alert, , , , ,

Osiris Crushed on Crohn’s Trial Design Flaw (OSIR)

burning-money-pic36Osiris Therapeutics, Inc. (NASDAQ: OSIR) is seeing its stock getting pounded this morning.  The company announced that it was ending enrollment at 210 patients in its Phase III trial evaluating its Prochymal for Crohn’s disease.  The reason is that the company believes a design flaw exists in the trial resulting in significantly higher than expected placebo response rates.
Read More »

Posted on: March 27, 2009 – 8:17 am in Biotech, Trading Alert,

Should You Chase Stem Cell Stocks? (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL)

money-stack-image15We are seeing massive gap-ups this morning in stem cell stocks.  President Obama is signing an executive order which will lift the Bush ban on funding of embryonic stem cell funding.  What is interesting here is that this is not really new news other than the timing and the formality.  The following prices are as of 8:19 AM EST.

  • Aastrom Biosciences, Inc. (NASDAQ: ASTM) +87% at $0.62
  • Cytori Therapeutics, Inc. (NASDAQ: CYTX) +38% at $3.20
  • Geron Corporation (NASDAQ: GERN) +29% at $4.99
  • Neostem, Inc. (AMEX: NBS) NOT TRADED
  • Osiris Therapeutics, Inc. (NASDAQ: OSIR) NOT TRADED…. in pact with Genzyme, but for adult stem cells.
  • StemCells Inc. (NASDAQ: STEM) +55% at $2.15
  • Thermogenesis Corp. (NASDAQ: KOOL) +41% at $0.57

Many of these stem cell stocks will trade more on a “vote of confidence” rather than over what this means as far as “new news” is concerned.

JON C. OGG

Posted on: March 9, 2009 – 7:29 am in Biotech, Politics, , , , , , ,

24/7 Wall St. Stock Volume And Price Alerts (OSIR)(AHII)(CIT)(ADM)(MRVL)

Cammonopoly_wideweb__430x3250Osiris Therapeutics (OSIR) started the day with a big surge. More details.

Animal Health (AHII) may be one of the worst performing stocks today.

Financial giant CIT (CIT) may have one of its best days in months.

Read More »

Posted on: November 4, 2008 – 12:53 pm in Research, , , , ,

Top Pre-Market Analyst Downgrades (FMR, GOL, HNSN, IMCL, MNST, OSIR, WYE)

These are some of the key downgrades or negative calls we are seeing from analysts this Friday morning with more than two hours to the open:

  • First Mercury (FMR) Cut to Neutral at JPMorgan.
  • GOL Linhas Areas Inteligentes S.A. (GOL) Cut to Underweight at JPMorgan.
  • Hansen Medical (HNSN) Cut to Neutral at Merriman Curhan Ford.
  • ImClone (IMCL) Cut to Hold at Citigroup.
  • Monster Worldwide (MNST) Cut to Neutral at JPMorgan.
  • Osiris Therapeutics (OSIR) Cut to Underperform at Jefferies.
  • Wyeth (WYE) Cut to Neutral at HSBC.

Jon C. Ogg
August 1, 2008

Posted on: August 1, 2008 – 6:33 am in Analyst Calls, , , , , , ,

Super Tuesday Election Winner: STEM CELLS (STEM, GERN, ASTM, IVGN, KOOL, NBS, OSIR)

Despite not knowing whom the ultimate winner of the 2008 Presidential election will be, it looks like stem cells may be one of the real bright spots as far as which area in biotech will be open for more funding down the road.  If the Democrats win this is a shoe in.  If McCain wins, the current research clamp-downs won’t likely be as stringent in 2009 and beyond as they are today.  If Romney stages a comeback, despite many thinking of him as a religious figure our indications are that he at worst would not be anywhere as tough on the stem cell studies as the current administration.  Public companies such as StemCells Inc. (NASDAQ: STEM), Geron Corporation (NASDAQ: GERN), Aastrom Biosciences, Inc. (NASDAQ: ASTM), and others are going to be watching closely.

If you look at Tradesports.com for the political futures, you can see the Presidential nominee futures right now if you want to make a determination where the actual money bets are going right now.  McCain is priced at $93.00 and Romney is now priced at $1.90, so this would indicate a 92.9% probability of a McCain nomination.  The Democrat race is much closer right now with Tradesports showing a Hillary Clinton nomination with a $54.60 price (down $8.40), and Obama with a $47.40 price (up $8.90).  So the futures are showing a McCain essentially as a shoe-in now, yet the Democrat race is still too close to call.  Guess what, this would be a win-win for stem cell research beyond this year.

Read More »

Posted on: February 6, 2008 – 9:33 am in Biotech, Politics, , , , , , , , , , , , , ,

Pre-Market Stock News (November 27, 2007)

Below is a snapshot of much of the pre-market news moving individual stocks this morning:

  • Activision (ATVI) raised guidance on Guitar Hero III sales; stock up 8% pre-market.
  • Barrier Therapeutics (BTRX) announced positive results of higher dose escalation clinical safety study with pramiconazole.
  • Casual Male (CMRG) indicated lower after missing earnings and guiding lower.
  • CIGNA (CI) is acquiring Great-West Healthcare for $1.5 Billion.
  • Citigroup (C) sold a $7.5 Billion stake to Abu Dhabi Fund.
  • GlobalSantaFe (GSF) has received a subpoena from the SEC seeking documents related to the company’s ongoing internal investigation.
  • Hydrogenics (HYGS) received a $1.7 million order for three fuel cell hybrid MiniBuses for an Expo in Spain.
  • Osiris Therapeutics (OSIR) announced positive one-year data from Chondrogen trial for knee repair in its preparation of adult stem cells formulated for direct injection into the knee.
  • Penford Corp (PENX) announced a 2 Million share common stock offering, although this was under the existing shelf offering.
  • Pharmacopeia (PCOP) and GlaxoSmithKline identified two new additional lead compounds that will trigger milestone payment of $1 million to Pharmacopeia.
  • Qiao Xing (XING) telegraphss medium and long-term business plans and will continue to take steps to ensure growth of 20% to 30% per year for the next 5-years.
  • Sepracor (SEPR) announced the completion of its SEC investigation and no enforcement action was recommended.
  • Smith & Nephew (SNN) announces precautionary knee recall.
  • Staples (SPLS) $0.42 EPS vs $0.40 est.
  • Tech Data (TECD) $0.73 EPS vs $0.60 est. (unsure if comparable) sales guidance for Q4 looks a tad light.
  • Tenet Healthcare (THC) entered into a new national insurance coverage agreement with UnitedHealthcare (UNH).

Jon C. Ogg
November 27, 2007

Jon Ogg produces the 24/7 Wall St. Special Situation Investing Newsletter; he does not own securities in the companies he covers.

Posted on: November 27, 2007 – 8:14 am in Pre-Market Activity, , , , , , , , , , , , , , , ,